(Q37633519)

21 August 2017

1 reference

title

Benefit-risk assessment of leflunomide: an appraisal of leflunomide in rheumatoid arthritis 10 years after licensing (English)

1 reference

21 August 2017

1 reference

Nicola Alcorn

1

1 reference

PubMed ID

19916579

21 August 2017

Sarah Saunders

series ordinal

2

1 reference

PubMed ID

19916579

21 August 2017

Rajan Madhok

series ordinal

3

1 reference

21 August 2017

1 January 2009

1 reference

21 August 2017

1 reference

21 August 2017

32

1 reference

21 August 2017

12

1 reference

21 August 2017

1123-1134

1 reference

https://scigraph.springernature.com/pub.10.2165/11316650-000000000-00000

21 August 2017

0 references

cites work

Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F11316650-000000000-00000

Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F11316650-000000000-00000

Therapeutic drug monitoring of A77 1726, the active metabolite of leflunomide: serum concentrations predict response to treatment in patients with rheumatoid arthritis.

21 January 2018

1 reference

12 December 2020

Leflunomide-induced acute hepatitis

1 reference

12 December 2020

Duration of rheumatoid arthritis influences the degree of functional improvement in clinical trials

1 reference

12 December 2020

Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group.

1 reference

12 December 2020

Rheumatoid arthritis complicated with acute interstitial pneumonia induced by leflunomide as an adverse reaction

1 reference

12 December 2020

Leflunomide use and the risk of interstitial lung disease in rheumatoid arthritis

1 reference

12 December 2020

Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine

1 reference

12 December 2020

Infliximab and leflunomide combination therapy in rheumatoid arthritis: an open-label study

1 reference

12 December 2020

Arthritis drug should be removed from market, says consumer group

1 reference

12 December 2020

Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis. Results of a randomized, placebo-controlled, phase II study

1 reference

12 December 2020

The efficacy and safety of leflunomide in patients with active rheumatoid arthritis: a five-year followup study

1 reference

12 December 2020

The effect of smoking on clinical, laboratory, and radiographic status in rheumatoid arthritis

1 reference

12 December 2020

Population pharmacokinetics and association between A77 1726 plasma concentrations and disease activity measures following administration of leflunomide to people with rheumatoid arthritis

1 reference

12 December 2020

Leflunomide can potentiate the anticoagulant effect of warfarin

1 reference

12 December 2020

Leflunomide-associated weight loss in rheumatoid arthritis

1 reference

12 December 2020

Japan deaths spark concerns over arthritis drug

1 reference

12 December 2020

Leflunomide: a review of its use in active rheumatoid arthritis

1 reference

12 December 2020

Which HAQ is best? A comparison of the HAQ, MHAQ and RA-HAQ, a difficult 8 item HAQ (DHAQ), and a rescored 20 item HAQ (HAQ20): analyses in 2,491 rheumatoid arthritis patients following leflunomide initiation

1 reference

12 December 2020

Joint erosions and patients with early rheumatoid arthritis

1 reference

12 December 2020

Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group

1 reference

12 December 2020

Leflunomide for the treatment of rheumatoid arthritis in clinical practice: incidence and severity of hepatotoxicity.

1 reference

12 December 2020

Leflunomide induced acute interstitial pneumonia.

1 reference

12 December 2020

Leflunomide use during the first 33 months after food and drug administration approval: experience with a national cohort of 3,325 patients

1 reference

12 December 2020

Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films

1 reference

12 December 2020

Clinical experience with leflunomide in rheumatoid arthritis. Leflunomide Investigators' Group.

1 reference

12 December 2020

Effectiveness and safety of infliximab combined with leflunomide in chronic polyarthritis

1 reference

12 December 2020

Cigarette smoking and rheumatoid arthritis severity

1 reference

12 December 2020

Efficacy and safety of leflunomide and predisposing factors for treatment response in patients with active rheumatoid arthritis: RELIEF 6-month data.

1 reference

12 December 2020

Predicting mortality in patients with rheumatoid arthritis

1 reference

12 December 2020

Rheumatoid arthritis treatment with weekly leflunomide: an open-label study.

1 reference

12 December 2020

A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis.

1 reference

12 December 2020

Effect of leflunomide on the peripheral nerves in rheumatoid arthritis

1 reference

12 December 2020

Leflunomide for treating rheumatoid arthritis

1 reference

12 December 2020

The immunosuppressant leflunomide inhibits lymphocyte proliferation by inhibiting pyrimidine biosynthesis.

1 reference

12 December 2020

Efficacy and safety of leflunomide 10 mg versus 20 mg once daily in patients with active rheumatoid arthritis: multinational double-blind, randomized trial

1 reference

12 December 2020

Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group

1 reference

12 December 2020

The safety and efficacy of leflunomide in combination with infliximab in rheumatoid arthritis

1 reference

12 December 2020

Induction of antinuclear antibodies in patients with rheumatoid arthritis treated with infliximab and leflunomide

1 reference

12 December 2020

Combination leflunomide and methotrexate (MTX) therapy for patients with active rheumatoid arthritis failing MTX monotherapy: open-label extension of a randomized, double-blind, placebo controlled trial

1 reference

12 December 2020

Long term evaluation of radiographic disease progression in a subset of patients with rheumatoid arthritis treated with leflunomide beyond 2 years

1 reference

12 December 2020

Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis

1 reference

12 December 2020

Combination therapy for rheumatoid arthritis: methotrexate and sulfasalazine together or with other DMARDs

1 reference

12 December 2020

Weekly dose of leflunomide for the treatment of refractory rheumatoid arthritis: an open pilot comparative study

1 reference

12 December 2020

Inhibition of JAK3 and STAT6 tyrosine phosphorylation by the immunosuppressive drug leflunomide leads to a block in IgG1 production

1 reference

12 December 2020

Leflunomide: a manageable safety profile.

1 reference

12 December 2020

Newer disease-modifying antirheumatic drugs and the risk of serious hepatic adverse events in patients with rheumatoid arthritis

1 reference

12 December 2020

Inhibition of neutrophil migration soon after initiation of treatment with leflunomide or methotrexate in patients with rheumatoid arthritis: findings in a prospective, randomized, double-blind clinical trial in fifteen patients

1 reference

12 December 2020

The influence of previous and concomitant leflunomide on the efficacy and safety of infliximab therapy in patients with rheumatoid arthritis; a longitudinal observational study

1 reference

12 December 2020

Effect of leflunomide on constitutive and inducible pathways of cellular eicosanoid generation

1 reference

12 December 2020

Risk of interstitial lung disease associated with leflunomide treatment in Korean patients with rheumatoid arthritis

1 reference

12 December 2020

Regulation of B cell function by the immunosuppressive agent leflunomide

1 reference

12 December 2020

Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire

1 reference

12 December 2020

Leflunomide in active rheumatoid arthritis: a prospective study in daily practice

1 reference

12 December 2020

The effects of leflunomide on clinical parameters and serum levels of IL-6, IL-10, MMP-1 and MMP-3 in patients with resistant rheumatoid arthritis

1 reference

12 December 2020

Modulation of inflammation and metalloproteinase expression in synovial tissue by leflunomide and methotrexate in patients with active rheumatoid arthritis. Findings in a prospective, randomized, double-blind, parallel-design clinical trial in thirt

1 reference

12 December 2020

Leflunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated T-lymphocytes from healthy humans

1 reference

12 December 2020

Methods of scoring the progression of radiologic changes in rheumatoid arthritis. Correlation of radiologic, clinical and laboratory abnormalities

1 reference

12 December 2020

Prevention of acetaminophen (APAP)-induced hepatotoxicity by leflunomide via inhibition of APAP biotransformation to N-acetyl-p-benzoquinone imine

1 reference

12 December 2020

Leflunomide for the treatment of rheumatoid arthritis: a systematic review and metaanalysis.

1 reference

12 December 2020

Examination of the risk of continuous leflunomide treatment on the incidence of infectious complications after joint arthroplasty in patients with rheumatoid arthritis

1 reference

12 December 2020

In vivo mechanism by which leflunomide controls lymphoproliferative and autoimmune disease in MRL/MpJ-lpr/lpr mice

1 reference

12 December 2020

Leflunomide and its metabolite A771726 are high affinity substrates of BCRP: implications for drug resistance

1 reference

12 December 2020

Leflunomide-associated infections in rheumatoid arthritis

1 reference

12 December 2020

A novel mechanism of action of the immunomodulatory drug, leflunomide: augmentation of the immunosuppressive cytokine, TGF-beta 1, and suppression of the immunostimulatory cytokine, IL-2.

1 reference

12 December 2020

Safety of leflunomide plus infliximab combination therapy in rheumatoid arthritis.

1 reference

12 December 2020

10.2165/11316650-000000000-00000

Identifiers

DOI

1 reference

21 August 2017

1 reference

PubMed ID

19916579